Citius Oncology (CTOR)announced the commercial launch of LYMPHIR. LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTOR:
- Citius Oncology to advance launch of Lymphir with Verix AI integration
- Citius Oncology Stockholders Approve Share Increase
- Citius Oncology Prepares LYMPHIR Launch for Q4 2025
- Citius Oncology announces distribution agreement with McKesson
- Strategic Positioning and Market Potential Drive Buy Rating for Citius Oncology’s Lymphir